
|Videos|December 18, 2020
Safety, efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton, Alex Delaney-Gesing
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
3
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
4
Why individualized glaucoma care remains essential amid uneven patient awareness
5














































